Loading...
Login/Register
Welcome
Profile
Log Off
text
title
chapter title
keyword
WHO Home
WHO Health Systems and Services
WHO Medicines
WHO sites
Medicines Documentation home
Search
Titles A-Z
Subjects
Keywords
Series and Periodicals
Publishers
Authors A-Z
Regions
Countries
Index
Sub-collections
Public
sub-collections
Expand Document
|
Expand Chapter
|
Full TOC
|
Printable HTML version
::
Themes & Keywords
·
Keywords
>
pharmaceuticals newsletter
WHO Pharmaceuticals Newsletter 1999, No. 05&06
(1999; 20 pages)
Table of Contents
Regulatory actions
Bromfenac: withdrawn: hepatotoxicity Saudi Arabia.
Capecitabine and coumarin derivatives: revised data sheet: potential interaction Roche, United States of America.
Chlormezanone: withdrawn: cutaneous reactions Saudi Arabia.
Cyclandelate: withdrawn: ineffective Saudi Arabia.
Dipyridamole: withdrawn: United States of America.
Fenfluramine and dexfenfluramine: withdrawn: cardiotoxicity: Saudi Arabia.
Flumazenil: revised data sheet: contraindications: Roche, United Kingdom.
Infliximab: new prescribing information: Centocor, United States of America.
Medicines Law: draft submitted to Parliament: Switzerland.
Metamizole sodium: marketing authorization suspended: Sweden.
Paracetamol: revised labelling: warnings concerning overdosage: Sweden.
Phenolphthalein in laxatives: withdrawn: risk of carcinogenicity: Saudi Arabia.
Teicoplanin: revised data sheet: risk of superinfection: Hoechst Marion Roussel, United Kingdom.
Terfenadine: withdrawn: cardiotoxicity: Saudi Arabia.
Tolcapone: withdrawn: hepatotoxicity: Australia.
Triamcinolone hexacetonide: revised data sheet: use during pregnancy: United Kingdom.
Drug surveillance
Angiotensin II receptor antagonists losartan and irbesartan: review of adverse reactions: Australia.
Asian remedy for menstrual cramps (“Koo Sar Pills”): lead poisoning in an adult reported: United States of America.
Azathioprine and allopurinol: interaction: Australia.
Echinacea: allergic reactions: Australia.
Vigabatrin: visual field defects: update: Australia.
New developments
Amprenavir: approved for HIV-1 infection: United States of America.
Orlistat: approved for obesity: United States of America.
New indications
New formulations
Newly approved products
Medical devices
Blood clot removal device: approved: United States of America.
Breast imaging device: approved: United States of America.
Haemodialysis tubing set: defective device recalled: Althin Medical, United States of America.
Hepatitis-C virus: first OTC home test approved: United States of America.
Temporomandibular joint prostheses: premarket approval required: United States of America.
Medication errors
Communications problems: delay in recognition of medication errors: United States of America.
Confusing directions: fatal overdosage: United States of America.
Medication error prevention: strategies: United States of America.
Similar packaging: potential for mistaken identity: United States of America.
Visual cues: clues to medication errors: United States of America.
General information
Product name placement, size and prominence in advertising: guidance available: United States of America.
Skin irritation and sensitization testing of generic transdermal drug products: draft guidance available: United States of America.
Veterinary medicine
Bacitracin methylene disalicylate soluble: approved for prevention and control of necrotic enteritis: United States of America.
Eprinomectin: approved for treatment of parasites in cattle: Switzerland.
Microbial effects of antimicrobial new animal drugs: assuring human safety: United States of America.
WHO Pharmaceuticals Newsletter 1999, No. 05&06
WHO.INT
World Health Organization
Essential Drugs and Medicines Policy
Contacts
|
E-mail scams
|
Employment
|
FAQs
|
Feedback
|
Privacy
|
RSS feeds
© WHO 2013
Last updated: May 3, 2013
Loading...
